Sangamo Therapeutics' (SGMO) cash on its balance sheet remains "an overhang" following Pfizer's (PFE) decision to terminate a hemophilia A gene therapy collaboration with the company, Truist Securities said in a Monday note.
The partnership and license agreement between the two companies are anticipated to close in Q1 next year and while the company's management had hinted that a biologics license application would "trigger a meaningful payment to help cash runway," it seems difficult now without a significant cash infusion in Q1 2025, analysts led by Nicole Germino wrote.
Truist Securities maintained a buy rating on the company's stock with a $7 price target.
SGMO shares were down 55% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.